
LEUVEN, Belgium, August 16, 2013 /PRNewswire/ —
Canada is first market outside the US and Europe where JETREA ® is approved
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has approved JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The priority review of the New Drug Submission for JETREA in Canada was conducted within 180 calendar days. Canada is the first market where JETREA® is approved outside the US and Europe. ThromboGenics’ partner Alcon holds the commercialization rights to JETREA® outside the US and will be responsible for the launch of the drug in Canada.
read all at
http://www.pharmalive.com/health-canda-approves-jetrea-for-vma
Ocriplasmin (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.[1]
References
1 Stalmans, P; Benz, MS; Gandorfer, A; Kampik, A; Girach, A; Pakola, S; Haller, JA; MIVI-TRUST Study, Group (2012 Aug 16). “Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.”. The New England journal of medicine 367 (7): 606–15. PMID 22894573.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on My Blog on Medicinal Chemistry.
LikeLike
Reblogged this on Vijaya Shastry Ph.D Physical Chemistry.
LikeLike
Reblogged this on GREEN MED CHEMISTRY.
LikeLike
Reblogged this on Med.Chem.in.Iceland.
LikeLike